About: Antiviral Agent Therapy Optimization in Special Populations of COVID-19 Patients

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Antiviral Agent Therapy Optimization in Special Populations of COVID-19 Patients Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Antiviral Agent Therapy Optimization in Special Populations of COVID-19 Patients
Creator	Li, Lu Hu, Yunzhen Jiang, Saiping Lu, Xiaoyang Wang, Rongrong »more»
source	Medline; PMC
abstract	Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is now a global outbreak of disease. The antiviral treatment acts as one of the most important means of SARS-CoV-2 infection. Alteration of physiological characteristics in special populations may lead to the change in drug pharmacokinetics, which may result in treatment failure or increased adverse drug reactions. Some potential drugs have shown antiviral effects on SARS-CoV-2 infections, such as chloroquine, hydroxychloroquine, favipiravir, lopinavir/ritonavir, arbidol, interferon alpha, and remedsivir. Here, we reviewed the literature on clinical effects in COVID-19 patients of these antiviral agents and provided the potential antiviral agent options for pregnant women, elderly patients, liver or renal dysfunction patients, and severe or critically ill patients receiving renal replacement therapy or ECMO after SARS-CoV-2 infection.
has issue date	2020-07-28(xsd:dateTime)
bibo:doi	10.2147/dddt.s259058
bibo:pmid	32801640
has license	cc-by-nc
sha1sum (hex)	28d8c4f47fb368408c0c40f21354be4583c21178
schema:url	https://doi.org/10.2147/dddt.s259058
resource representing a document's title	Antiviral Agent Therapy Optimization in Special Populations of COVID-19 Patients
has PubMed Central identifier	PMC7396737
has PubMed identifier	32801640
schema:publication	Drug Des Devel Ther
resource representing a document's body	covid:28d8c4f47fb368408c0c40f21354be4583c21178#body_text
is schema:about of	named entity 'antiviral agents' named entity 'effects' named entity 'renal dysfunction' named entity 'receiving' named entity 'Antiviral' »more»

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software